Amnis Announces Release of New Image Data Analysis Software
Amnis releases IDEAS version 3.0 statistical image analysis software.
SEATTLE, WA-April 10, 2008-Amnis Corporation announced today a major new release of its IDEAS® statistical image analysis software. IDEAS version 3.0 incorporates greatly expanded analytical capabilities while maintaining an emphasis on ease of use.
IDEAS 3.0 provides the user with dozens of new image feature calculations and improves existing features to strengthen morphological data analysis. The new software also provides the user with much greater flexibility in defining specific areas of interest within a cell with eight new masking functions. Finally, ease of use has been improved with a new fluorescence crosstalk compensation process, automated statistical summaries of batch-processed data, and an all-new wizard system. Amnis is providing IDEAS 3.0 at no charge to all ImageStream sites that are under warranty or service contract.
“The commercial release of IDEAS 3.0 is a major accomplishment for Amnis,” said David Basiji, Ph.D., Amnis’ president and chief executive officer. “By making the IDEAS software more powerful and easier to use, we’re working to bring the benefits of quantitative cell image analysis to an even wider audience. This release lays the foundation for future versions that will make image data analysis far faster, more intuitive, and more automated.”
Cathy Zimmerman, Amnis’ director of software, added, “Our software team works closely with customers and with the scientists at Amnis to insure that we are developing the most relevant and useful tools possible. We have been very gratified by the exceptionally positive response this release has received so far.”
Amnis Corporation ( www.amnis.com) develops, manufactures and markets the ImageStream system for high speed imaging of cells in flow. The system generates six high resolution microscopic images of cells as they flow through the instrument at rates up to 300 cells per second. The system is unique in its ability to image tens of thousands of cells in minutes without the need to make slides. The IDEAS image analysis package, an integral part of the ImageStream system, is a highly sophisticated yet easy to use tool for processing hundreds of thousands of images at a time. IDEAS enables highly advanced research applications in hematology, immunology, oncology and provides a critical foundation for the company's clinical applications development.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
